12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
NCT00456794
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
325
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
Istradefylline (KW-6002)
Sponsor
Kyowa Kirin, Inc.